Search

Search Constraints

You searched for: Author/Creator Zografos, Eleftherios

Search Results

1. 2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study. (20th October 2022)

2. 2022-RA-1144-ESGO Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study. (20th October 2022)

3. 2022-RA-1194-ESGO Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study. (20th October 2022)

4. 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. (20th October 2022)

5. 2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial. (20th October 2022)

6. 39/#452 Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the garnet study. (4th December 2022)

7. 6/#455 Management of immune-related adverse events in patients with solid tumors treated with dostarlimab in the garnet study. (4th December 2022)

8. Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. (October 2019)

9. O007/#456 Post-hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. (4th December 2022)